Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| aTYR PHARMA INCATYR · Entity 7233 | Director | May 11, 2026 | May 13, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
aTYR PHARMA INC
Report date May 11, 2026 · Filed May 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2036-05-11 | Direct | 50,000 |
Reported balance
After 2026-05-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-11 · Grant · Acquired 50,000 · Balance 50,000 F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2026 Filed May 13, 2026 20:10 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0001602225-26-000003 · ownership.xml · derivative · entry 1 Zaknoen Sara · CIK 0001602225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2036-05-11 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 01, 2025 Filed May 2, 2025 21:25 UTC | aTYR PHARMA INC ATYR · Entity 7233 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $3.34 | $0.00 |
DisclosureSEC source: 0000950170-25-062947 · ownership.xml · derivative · entry 1 Zaknoen Sara · CIK 0001602225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-05-01 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 1, 2026 or (ii) the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 22, 2024 Filed May 23, 2024 23:11 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $1.86 | $0.00 |
DisclosureSEC source: 0000950170-24-064209 · ownership.xml · derivative · entry 1 Zaknoen Sara · CIK 0001602225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2034-05-22 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 22, 2025 or (ii) the Issuer's 2025 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:33 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.52 | $0.00 |
DisclosureSEC source: 0001209191-23-031024 · doc4.xml · derivative · entry 1 Zaknoen Sara · CIK 0001602225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2033-05-17 F1 · derivative.exercise_date: The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 17, 2024 or (ii) the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:56 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionRestricted Stock Unit · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026070 · doc4.xml · derivative · entry 2 Zaknoen Sara · CIK 0001602225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: RSUs convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs fully vested one year from the grant date which was April 26, 2022. F3 · derivative.expiration_date: The RSUs fully vested one year from the grant date which was April 26, 2022. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 20:56 UTC | aTYR PHARMA INC LIFE · Entity 7233 | Exercise / conversionCommon stock | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-026070 · doc4.xml · nonDerivative · entry 1 Zaknoen Sara · CIK 0001602225 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on April 26, 2022. F2 · price: RSUs convert into common stock on a one-for-one basis. Read SEC document |
| April 26, 2022 Filed Apr 28, 2022 23:57 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-026096 · doc4.xml · derivative · entry 1 Zaknoen Sara · CIK 0001602225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The RSUs, granted pursuant to the Issuer's non-employee director compensation policy, vest in full on the earlier of (i) April 26, 2023 or (ii) the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. F2 · derivative.expiration_date: The RSUs, granted pursuant to the Issuer's non-employee director compensation policy, vest in full on the earlier of (i) April 26, 2023 or (ii) the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors. Read SEC document |
| May 21, 2021 Filed May 26, 2021 01:02 UTC | aTYR PHARMA INC LIFE · Entity 7233 | GrantStock Option (right to buy) · Derivative | 2,285 | $0.00 Strike: $4.45 | $0.00 |
DisclosureSEC source: 0001209191-21-035829 · doc4.xml · derivative · entry 1 Zaknoen Sara · CIK 0001602225 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,285 Underlying: Common Stock · 2,285 shares Expires 2031-05-21 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 36 equal monthly installments beginning June 21, 2021, such that this option will be fully exercisable on May 21, 2024, subject to the recipient's continued service on the Issuer's Board of Directors. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.